BioStem Technologies, Inc.
BSEM
$14.50
-$0.03-0.21%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 2,258.90% | 6,872.30% | 7,173.77% | 1,342.67% | 205.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,258.90% | 6,872.30% | 7,173.77% | 1,342.67% | 205.45% |
| Cost of Revenue | 1,203.81% | 1,718.49% | 2,100.49% | 416.88% | 36.60% |
| Gross Profit | 2,366.94% | 8,104.12% | 8,253.58% | 1,515.90% | 249.71% |
| SG&A Expenses | 1,751.83% | 1,686.82% | 800.76% | 210.28% | 128.18% |
| Depreciation & Amortization | 1.43% | -9.83% | -7.89% | -5.54% | -9.68% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1,679.56% | 1,636.55% | 823.34% | 205.28% | 114.35% |
| Operating Income | 1,605.56% | 425.02% | 233.04% | 42.22% | 20.36% |
| Income Before Tax | 695.05% | 403.90% | 224.08% | 27.29% | -73.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 543.40% | 322.85% | 190.99% | 27.29% | -73.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 543.40% | 322.85% | 190.99% | 26.34% | -92.95% |
| EBIT | 1,605.56% | 425.02% | 233.04% | 42.22% | 20.36% |
| EBITDA | 1,746.36% | 434.39% | 236.87% | 42.81% | 20.39% |
| EPS Basic | 466.49% | 281.33% | 170.06% | 34.94% | -67.16% |
| Normalized Basic EPS | 1,024.54% | 347.18% | 195.56% | 51.66% | 4.53% |
| EPS Diluted | 380.70% | 236.36% | 148.26% | 34.94% | -67.16% |
| Normalized Diluted EPS | 814.25% | 288.71% | 166.59% | 51.66% | 4.53% |
| Average Basic Shares Outstanding | 20.94% | 22.91% | 29.86% | 13.23% | 15.51% |
| Average Diluted Shares Outstanding | 56.54% | 61.03% | 86.36% | 13.23% | 15.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |